the receptor binding domain of mers-cov: the dawn of vaccine and treatment development

Clicks: 252
ID: 188657
2014
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #75 of 246 articles by views in Bioorganic & medicinal chemistry letters

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 246 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The newly emerged Middle East respiratory syndrome coronavirus (MERS-CoV) is becoming another “SARS-like” threat to the world. It has an extremely high death rate (∼50%) as there is no vaccine or efficient therapeutics. The identification of the structures of both the MERS-CoV receptor binding domain (RBD) and its complex with dipeptidyl peptidase 4 (DPP4), raises the hope of alleviating this currently severe situation. In this review, we examined the molecular basis of the RBD-receptor interaction to outline why/how could we use MERS-CoV RBD to develop vaccines and antiviral drugs.
Reference Key
zhou2014journalthe Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Nan Zhou;Yun Zhang;Jin-Chun Zhang;Ling Feng;Jin-Ku Bao
Journal Bioorganic & medicinal chemistry letters
Year 2014
DOI
10.1016/j.jfma.2013.11.006
URL
http://www.sciencedirect.com/science/article/pii/S0929664613004026
Keywords
coronavirus drug design middle east

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.